干眼病相关症状变化检测问卷的编制。

Development of a Questionnaire for Detecting Changes in Dry Eye Disease-Related Symptoms.

机构信息

IOBA (Institute of Applied Ophthalmobiology) (J.P.-F., M.C., A.E.-d.-S., I.F., M.J.G.-G.), University of Valladolid, Valladolid, Spain; CIBER-BBN (Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine) (J.P.-F., M.C., A.E.-d.-S., I.F.), Spain; and Department of Ophthalmology and Ocular GvHD Competence Center (P.S.), Medical Faculty, University of Cologne, Cologne, Germany.

出版信息

Eye Contact Lens. 2021 Jan 1;47(1):8-14. doi: 10.1097/ICL.0000000000000693.

DOI:10.1097/ICL.0000000000000693

PMID:32097186

Abstract

OBJECTIVES

Determining the changes in symptomatology suffered by dry eye disease (DED) patients after an intervention is difficult because there is only one validated questionnaire specifically designed to measure these changes and it is somewhat complex. This work uses a simplified questionnaire to evaluate the changes in DED-related symptoms.

METHODS

A new questionnaire based on a global rating of change scale was designed. The Change in Dry Eye Symptoms Questionnaire (CDES-Q) consists of 2 questions: CDES-Q1 asks for the change in symptoms ("better," "same," or "worse") relative to a determined previous time and CDES-Q2 quantifies this change (range: 0 to +100). To evaluate the CDES-Q, a prospective observational study was performed. At baseline (V1; day-0), DED-related symptoms were evaluated using the ocular surface disease index (OSDI). In the post-treatment visit (V2; day-90), OSDI, Symptoms Assessment Questionnaire in Dry Eye (SANDE) II, and CDES-Q were used. Also, clinical evaluations were performed in each visit.

RESULTS

Thirty-six patients were included. At V2, OSDI, SANDE II, and CDES-Q showed a significant reduction in symptoms (-7.17±12.73, P=0.0021; -11.29±20.95, P=0.0035; -25.28±42.28, P=0.0011, respectively). Patients who answered "better" in CDES-Q1 showed a significantly lower SANDE II than those who answered "same" or "worse," while SANDE II did not discriminate between these groups.

CONCLUSIONS

CDES-Q can be a useful tool for the evaluation of changes in DED-related symptoms. It is simple and better discriminates patients without changes from those who suffered a worsening than SANDE II.

摘要

目的

由于专门用于衡量这些变化的问卷只有一个，且较为复杂，因此评估干眼疾病（DED）患者干预后的症状变化较为困难。本研究采用简化问卷来评估 DED 相关症状的变化。

方法

设计了一种基于总体变化评分的新问卷。干眼症状变化问卷（CDES-Q）由两个问题组成：CDES-Q1 询问症状相对于特定先前时间的变化（“更好”“相同”或“更差”），CDES-Q2 量化这种变化（范围：0 至+100）。为了评估 CDES-Q，进行了一项前瞻性观察性研究。在基线（V1；第 0 天）时，使用眼表面疾病指数（OSDI）评估 DED 相关症状。在治疗后访视（V2；第 90 天）时，使用 OSDI、干眼症状评估问卷（SANDE）Ⅱ和 CDES-Q。在每次访视中还进行了临床评估。

结果

共纳入 36 例患者。在 V2 时，OSDI、SANDE II 和 CDES-Q 的症状评分均显著降低（-7.17±12.73，P=0.0021；-11.29±20.95，P=0.0035；-25.28±42.28，P=0.0011）。在 CDES-Q1 中回答“更好”的患者的 SANDE II 评分显著低于回答“相同”或“更差”的患者，而 SANDE II 不能区分这两组患者。